Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Molecular Invests In, Will Collaborate with Drug Discovery Company


OXFORD, UK--Oxford Molecular Group here has entered into an agreement to invest as much as £5 million in Cambridge Drug Discovery, a new company that will specialize in providing advanced high-throughput screening services. Through a close collaboration with Cambridge, Oxford will offer an integrated drug design, synthesis, and screening service. Following the investment, Cambridge's services will be sold through Oxford's sales network.

Cambridge was recently founded by four former Pfizer researchers. Their firm promises to combine state-of-the-art robotic screening technology with drug targets derived from academic collaborations to become a leader in the market for high-throughput screening services. They will screen either novel or nonproprietary targets, design high-throughput screening assays, and provide consulting services.

Under terms of the deal, Oxford will pay £2 million in cash for 19.99 percent of Cambridge, with the remaining shares being held by Cambridge's founders. Oxford will also offer up to £2 million as a loan and £1 million for preferred shares that could ultimately raise its stake to 30 percent. The agreement also gives Oxford the option to acquire the remainder of Cambridge in either three or four years.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.